Atara Biotherapeutics (NASDAQ:ATRA)‘s stock had its “buy” rating reiterated by analysts at Cowen in a research report issued on Friday, TipRanks reports.
ATRA has been the topic of a number of other research reports. William Blair reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Thursday, May 16th. Roth Capital began coverage on shares of Atara Biotherapeutics in a research note on Friday. They issued a “buy” rating and a $30.00 price target on the stock. BidaskClub upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 10th. ValuEngine cut shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 17th. Finally, Wedbush restated an “outperform” rating on shares of Atara Biotherapeutics in a research note on Wednesday, May 29th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Atara Biotherapeutics has a consensus rating of “Buy” and a consensus price target of $36.50.
Shares of ATRA traded down $0.42 during mid-day trading on Friday, reaching $15.16. The company’s stock had a trading volume of 872,463 shares, compared to its average volume of 608,858. The stock has a market cap of $837.55 million, a PE ratio of -2.88 and a beta of 2.10. The company has a current ratio of 7.80, a quick ratio of 7.80 and a debt-to-equity ratio of 0.06. Atara Biotherapeutics has a 52 week low of $11.89 and a 52 week high of $43.95. The company’s fifty day moving average price is $13.71 and its two-hundred day moving average price is $24.97.
Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.60) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.45) by ($0.15). Research analysts anticipate that Atara Biotherapeutics will post -5.71 EPS for the current year.
In other Atara Biotherapeutics news, Director Eric Dobmeier purchased 2,000 shares of the company’s stock in a transaction dated Thursday, June 27th. The shares were acquired at an average price of $19.50 per share, for a total transaction of $39,000.00. Following the completion of the purchase, the director now owns 16,000 shares of the company’s stock, valued at $312,000. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 7.00% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC lifted its holdings in Atara Biotherapeutics by 5.1% in the first quarter. SG Americas Securities LLC now owns 10,432 shares of the biotechnology company’s stock valued at $415,000 after acquiring an additional 503 shares during the period. Oppenheimer & Co. Inc. raised its stake in shares of Atara Biotherapeutics by 15.2% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 10,132 shares of the biotechnology company’s stock worth $203,000 after buying an additional 1,340 shares during the period. Manchester Capital Management LLC acquired a new position in shares of Atara Biotherapeutics during the 1st quarter worth approximately $56,000. DekaBank Deutsche Girozentrale increased its position in shares of Atara Biotherapeutics by 22.2% during the first quarter. DekaBank Deutsche Girozentrale now owns 8,800 shares of the biotechnology company’s stock worth $356,000 after purchasing an additional 1,600 shares in the last quarter. Finally, Xact Kapitalforvaltning AB increased its position in shares of Atara Biotherapeutics by 37.3% during the first quarter. Xact Kapitalforvaltning AB now owns 8,100 shares of the biotechnology company’s stock worth $322,000 after purchasing an additional 2,200 shares in the last quarter. 91.79% of the stock is owned by hedge funds and other institutional investors.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Read More: How to interpret the current ratio
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.